In the case of intrahepatic cholangiocarcinoma and hepatocellular carcinoma, patients can be divided into two subgroups on the basis of TIGIT expression in tumor-infiltrating CD8+ T cells, which is important for the choice of the right therapy [58]. This evidence concerns the gene CD8A and neoplasm.